Medical School
- DO, A.T. Still University - School of Osteopathic Medicine in Arizona
Graduate School
- MS, Georgetown University
Undergraduate School
- BA, University of California–Berkeley (CA)
Internship
- Providence Sacred Heart Medical Center Program
Residency
- University Hospital/Cincinnati Children's/University of Cincinnati College of Medicine Program, Chief Resident, Dermatology
Fellowships
- Stanford University Program, Clinical Research Fellowship
Department
DermatologyProfessional Titles
- Assistant Professor of Dermatology
- Associate Director of Clinical Research, Dermatology
Research Interests
My research has focused on epidermolysis bullosa, including gene therapy, clinical trials, care of adults, and investigating the development of squamous cell carcinoma. In the last few years, my research interests have expanded to include hidradenitis suppurativa and immunobullous diseases.Publications
- Pathmarajah P, Eid E, Nazaroff J, So J, Mittal V, Harris N, Li S, Lucky AW, Gorell ES, Peoples KG, Pope E, Lara-Corrales I, Paller AS, Wiss K, Perman MJ, Eichenfield LF, Levy ML, Morel KD, García-Romero MT, McCuaig CC, Saber M, Marinkovich MP, Oro A, Bruckner AL, Tang JY. Functional genotype classification groups distinguish disease severity in recessive dystrophic epidermolysis bullosa. Br J Dermatol. 2025 Jan 10. [Epub ahead of print] PubMed PMID: 39790012
- Sabharwal K, Blanchard I, Gorell ES, Iqneibi M, Lucky AW, Worhunsky DJ. Junctional Epidermolysis Bullosa With Pyloric Atresia Complicated by Esophageal Atresia and Nephrotic Syndrome: A Case Report and Review of the Literature. Pediatr Dermatol. 2025 Jul-Aug;42(4):849-854. PubMed PMID: 40033822
- Tang JY, Marinkovich MP, Wiss K, McCarthy D, Truesdale A, Chiou AS, Eid E, McIntyre JK, Bailey I, Furukawa LK, Gorell ES, Harris N, Khosla RK, Peter Lorenz H, Lu Y, Nazaroff J, Grachev ID, Moore AJ. Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial. Lancet. 2025 Jul 12;406(10499):163-173. PubMed PMID: 40570869
- Mackenzie E, Lucky AW, Gorell ES. A call to action to address transition of care in pediatric dermatology. Pediatr Dermatol. 2024 Nov-Dec;41(6):1121-1122. PubMed PMID: 39563639
- Okata-Karigane U, Pathmarajah P, Gorell ES, Sum K, Yekrang K, Phung M, Barriga M, Udrizar P, Bailey I, Li S, Lu Y, Tang JY, Chiou AS. Evaluation of antipruritic effects of serlopitant, a neurokinin 1 receptor antagonist, in patients with epidermolysis bullosa: A phase 2 randomized controlled trial. J Eur Acad Dermatol Venereol. 2024 Jul 1. [Epub ahead of print] PubMed PMID: 38949042
- Iqneibi M, Gorell ES, Lucky AW. To prevent pain and anxiety, culture samples may be obtained from wound dressings. Pediatr Dermatol. 2024 May-Jun;41(3):563-564. PubMed PMID: 38743451
- So JY, Nazaroff J, Yenamandra VK, Gorell ES, Harris N, Fulchand S, Eid E, Dolorito JA, Marinkovich MP, Tang JY. Functional genotype-phenotype associations in recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol. 2024 Sep;91(3):448-456. PubMed PMID: 38735484
- Abreu Molnar B, Levin L, Yun D, Morel K, Wiss K, Wieser J, Ward C, Trice H, Garcia-Romero MT, Stephenson A, Provost A, Price HN, Perman MJ, Moxon M, Moeves B, McCuaig CC, McCarthy C, Lucky AW, Levy ML, Lee M, Lara-Corrales I, Henner N, Halliburton N, Griffith E, Gorell E, Glick S, Eichenfield L, Collins C, Bruckner AL, Boulrice B, Bayliss S, Badger K, Paller AS. Inpatient management of epidermolysis bullosa: Consensus-based hands-on instructions for neonates and postneonates. J Am Acad Dermatol. 2024 Aug;91(2):290-299. PubMed PMID: 38604489
- Singh A, Gorell ES, Lucky AW. Topical everolimus therapy for epidermal nevi associated with woolly hair nevus in a patient with a mosaic HRAS mutation. Pediatr Dermatol. 2024 Sep-Oct;41(5):871-873. PubMed PMID: 38558293
- Iqneibi M, Gorell ES, Lucky AW. To prevent pain and anxiety, culture samples may be obtained from wound dressings. Pediatr Dermatol. 2024 May-Jun;41(3):563-564. PubMed PMID: 38743451
- Abreu Molnar B, Levin L, Yun D, Morel K, Wiss K, Wieser J, Ward C, Trice H, Garcia-Romero MT, Stephenson A, Provost A, Price HN, Perman MJ, Moxon M, Moeves B, McCuaig CC, McCarthy C, Lucky AW, Levy ML, Lee M, Lara-Corrales I, Henner N, Halliburton N, Griffith E, Gorell E, Glick S, Eichenfield L, Collins C, Bruckner AL, Boulrice B, Bayliss S, Badger K, Paller AS. Inpatient management of epidermolysis bullosa: Consensus-based hands-on instructions for neonates and postneonates. J Am Acad Dermatol. 2024 Aug;91(2):290-299. PubMed PMID: 38604489
- Okata-Karigane U, Pathmarajah P, Gorell ES, Sum K, Yekrang K, Phung M, Barriga M, Udrizar P, Bailey I, Li S, Lu Y, Tang JY, Chiou AS. Evaluation of antipruritic effects of serlopitant, a neurokinin 1 receptor antagonist, in patients with epidermolysis bullosa: A phase 2 randomized controlled trial. J Eur Acad Dermatol Venereol. 2024 Jul 1. [Epub ahead of print] PubMed PMID: 38949042
- So JY, Nazaroff J, Yenamandra VK, Gorell ES, Harris N, Fulchand S, Eid E, Dolorito JA, Marinkovich MP, Tang JY. Functional genotype-phenotype associations in recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol. 2024 May 11. [Epub ahead of print] PubMed PMID: 38735484
- Singh A, Gorell ES, Lucky AW. Topical everolimus therapy for epidermal nevi associated with woolly hair nevus in a patient with a mosaic HRAS mutation. Pediatr Dermatol. 2024 Apr 1. [Epub ahead of print] PubMed PMID: 38558293
- Mackenzie E, Lucky AW, Gorell ES. A call to action to address transition of care in pediatric dermatology. Pediatr Dermatol. 2024 Nov-Dec;41(6):1121-1122. PubMed PMID: 39563639
- Lucky AW, Gorell E. Epidermolysis Bullosa with Pyloric Atresia. 2008 Feb 22 [updated 2023 Jan 26]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. PMID: 20301336.
- Aggarwal P, Gorell ES, Flood KS, Spicknall K, Breneman D. An uncommon presentation of cutaneous dissemination of gout. JAAD Case Rep. 2023 Jan;31:89-92. PubMed PMID: 36545484
- Rangu S, Collins J, García-Romero MT, Augsburger BD, Bruckner AL, Diaz LZ, Eichenfield LF, Faig W, Gorell ES, Lefferdink R, Lucky AW, Morel KD, Paller AS, Park H, Pastrana-Arellano E, Peoples K, Wiss K, Perman MJ, Castelo-Soccio L. Assessing pain catastrophizing and functional disability in pediatric epidermolysis bullosa patients. Pediatr Dermatol. 2023 May-Jun;40(3):422-427. PubMed PMID: 36579717
- Betancourt NJ, Sum K, Gorell ES, Tang JY, Chiou AS. Asymptomatic, microscopic hematuria in epidermolysis bullosa: A single center retrospective case series. J Am Acad Dermatol. 2022 Dec;87(6):1419-1421. PubMed PMID: 36007691
- So JY, Nazaroff J, Iwummadu CV, Harris N, Gorell ES, Fulchand S, Bailey I, McCarthy D, Siprashvili Z, Marinkovich MP, Tang JY, Chiou AS. Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa. Orphanet J Rare Dis. 2022 Oct 17;17(1):377. PubMed PMID: 36253825
- So JY, Fulchand S, Wong CY, Li S, Nazaroff J, Gorell ES, de Souza MP, Murrell DF, Teng JM, Chiou AS, Tang JY. A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplex. Orphanet J Rare Dis. 2022 Jul 15;17(1):270. PubMed PMID: 35841105
- Schräder NHB, Gorell ES, Stewart RE, Duipmans JC, Harris N, Perez VA, Tang JY, Wolff AP, Bolling MC. Cannabinoid use and effects in patients with epidermolysis bullosa: an international cross-sectional survey study. Orphanet J Rare Dis. 2021 Sep 6;16(1):377. PubMed PMID: 34488820
- Tang JY, Marinkovich MP, Lucas E, Gorell E, Chiou A, Lu Y, Gillon J, Patel D, Rudin D. A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa. Orphanet J Rare Dis. 2021 Apr 13;16(1):175. PubMed PMID: 33849616
- Fulchand S, Harris N, Li S, Barriga M, Gorell E, De Souza M, Murrell D, Marinkovich MP, Krishna Yenamandra V, Tang JY. Patient-reported outcomes and quality of life in dominant dystrophic epidermolysis bullosa: A global cross-sectional survey. Pediatr Dermatol. 2021 Sep;38(5):1198-1201. PubMed PMID: 34515355
- Solis DC, Teng C, Gorell ES, Barriga M, Nazaroff J, Li S, Lu Y, Bruckner A, Marinkovich MP, Tang JY. Classification of 2 distinct wound types in recessive dystrophic epidermolysis bullosa: A retrospective and cohort natural history study. J Am Acad Dermatol. 2021 Nov;85(5):1296-1298. PubMed PMID: 32896597
- Eng VA, Solis DC, Gorell ES, Choi S, Nazaroff J, Li S, de Souza MP, Murrell DF, Marinkovich MP, Tang JY. Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: A global cross-sectional survey. J Am Acad Dermatol. 2021 Nov;85(5):1161-1167. PubMed PMID: 32199895
- Solis DC, Gorell ES, Teng C, Barriga M, Nazaroff J, Li S, Subica A, Lu Y, Marinkovich MP, Tang JY. Clinical characteristics associated with increased wound size in patients with recessive dystrophic epidermolysis bullosa. Pediatr Dermatol. 2021 May;38(3):704-706. PubMed PMID: 33749033
- Lucky AW, Whalen J, Rowe S, Marathe KS, Gorell E. Diagnosis and Care of the Newborn with Epidermolysis Bullosa. Neoreviews. 2021 Jul;22(7):e438-e451. PubMed PMID: 34210808
- Gorell ES, Wolstencroft PW, de Souza MP, Murrell DF, Linos E, Tang JY. Financial burden of epidermolysis bullosa on patients in the United States. Pediatr Dermatol. 2020 Nov;37(6):1198-1201. PubMed PMID: 32897588
- Khaddour K, Gorell ES, Dehdashti F, Tang JY, Ansstas G. Induced Remission of Metastatic Squamous Cell Carcinoma with an Immune Checkpoint Inhibitor in a Patient with Recessive Dystrophic Epidermolysis Bullosa. Case Rep Oncol. 2020 May-Aug;13(2):911-915. PubMed PMID: 32884539
- Eichstadt S, Barriga M, Ponakala A, Teng C, Nguyen NT, Siprashvili Z, Nazaroff J, Gorell ES, Chiou AS, Taylor L, Khuu P, Keene DR, Rieger K, Khosla RK, Furukawa LK, Lorenz HP, Marinkovich MP, Tang JY. Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa. JCI Insight. 2019 Oct 3;4(19). PubMed PMID: 31578311
- Siprashvili Z, Nguyen NT, Gorell ES, Loutit K, Khuu P, Furukawa LK, Lorenz HP, Leung TH, Keene DR, Rieger KE, Khavari P, Lane AT, Tang JY, Marinkovich MP. Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa. JAMA. 2016 Nov 1;316(17):1808-1817. PubMed PMID: 27802546
- Danial C, Adeduntan R, Gorell ES, Lucky AW, Paller AS, Bruckner AL, Pope E, Morel KD, Levy ML, Li S, Gilmore ES, Lane AT. Evaluation of Treatments for Pruritus in Epidermolysis Bullosa. Pediatr Dermatol. 2015 Sep-Oct;32(5):628-34. PubMed PMID: 25557557
- Gorell ES, Nguyen N, Siprashvili Z, Marinkovich MP, Lane AT. Characterization of patients with dystrophic epidermolysis bullosa for collagen VII therapy. Br J Dermatol. 2015 Sep;173(3):821-3. PubMed PMID: 25703736
- Gorell ES, Leung TH, Khuu P, Lane AT. Purified type I collagen wound matrix improves chronic wound healing in patients with recessive dystrophic epidermolysis bullosa. Pediatr Dermatol. 2015 Mar-Apr;32(2):220-5. PubMed PMID: 25557742
- Danial C, Adeduntan R, Gorell ES, Lucky AW, Paller AS, Bruckner A, Pope E, Morel KD, Levy ML, Li S, Gilmore ES, Lane AT. Prevalence and characterization of pruritus in epidermolysis bullosa. Pediatr Dermatol. 2015 Jan-Feb;32(1):53-9. PubMed PMID: 25236506
- Gorell E, Nguyen N, Lane A, Siprashvili Z. Gene therapy for skin diseases. Cold Spring Harb Perspect Med. 2014 Apr 1;4(4):a015149. PubMed PMID: 24692191
- Spitale RC, Cheng MY, Chun KA, Gorell ES, Munoz CA, Kern DG, Wood SM, Knaggs HE, Wulff J, Beebe KD, Chang AL. Differential effects of dietary supplements on metabolomic profile of smokers versus non-smokers. Genome Med. 2012 Feb 23;4(2):14. PubMed PMID: 22360970
- Sbicca JA, Gorell ES, Peng DH, Lane AT. A follow-up survey of the integrity of the dermatology National Resident Matching Program. J Am Acad Dermatol. 2012 Sep;67(3):429-35. PubMed PMID: 22088426
- Gorell ES, Tichy AL, Lane AT. Successful investigational new drug preparation without reinventing the wheel. J Invest Dermatol. 2011 May;131(5):996-8. PubMed PMID: 21494234
- Barreto-Chang OL, Gorell ES, Yamaguma MA, Lane AT. Diagnosis of pilomatricoma using an otoscope. Pediatr Dermatol. 2010 Sep-Oct;27(5):554-7. PubMed PMID: 20807359
- Fong KD, Hu D, Eichstadt SL, Gorell E, Munoz CA, Lorenz HP, Chang AL. ??????Initial clinical experience using a novel ultraportable negative pressure wound therapy device. Wounds. 2010 Sep;22(9):230-6. PubMed PMID: 25901554
- Sbicca JA, Gorell ES, Kanzler MH, Lane AT. The integrity of the dermatology National Resident Matching Program: results of a national study. J Am Acad Dermatol. 2010 Oct;63(4):594-601. PubMed PMID: 20599295
- Gorell E, Lee C, Muñoz C, Chang AL. Adoption of Western culture by Californian Asian Americans: attitudes and practices promoting sun exposure. Arch Dermatol. 2009 May;145(5):552-6. PubMed PMID: 19451499
- Janjua R, Munoz C, Gorell E, Rehmus W, Egbert B, Kern D, Chang AL. A two-year, double-blind, randomized placebo-controlled trial of oral green tea polyphenols on the long-term clinical and histologic appearance of photoaging skin. Dermatol Surg. 2009 Jul;35(7):1057-65. PubMed PMID: 19469799
Professional Memberships
- Journal: Pediatric Dermatology, Associate Editor
- Pediatric Dermatology Research Alliance, Member
- American Academy of Dermatology, Member
Practice Locations
UCHealth Dermatology Clinic - Anschutz Medical Campus1665 Aurora Ct
3rd Floor, Anschutz Cancer Pavilion
Aurora, CO 80045
720-848-0500
Children's Colorado Health Pavilion
860 N Potomac Cir
Aurora, CO 80111
720-777-1234
Hospital Affiliation
- University of Colorado Hospital
- Children's Hospital Colorado
Specialty Information
Specialties- Dermatology, Board Certification
- Skin, Hair and Nails
Clinical Interests
Complex medical dermatology including: epidermolysis bullosa and other genetic skin conditions, autoimmune blistering diseases (such as pemphigus, pemphigoid), hidradenitis suppurativa. I see patients at both Children's Hospital of Colorado and UCHealth, and focus on the transition of care from pediatric to adult practice, particularly for patients with complex or rare skin conditions. As the Associate Director of Clinical Research, I also spend time on clinical research projects including clinical trials.
Care Philosophy
I specialize in complex medical dermatology, including transition of care from pediatric to adult care. I strive to provide compassionate, personalized treatment for the whole patient, recognizing that skin diseases can impact a patient's emotional well-bring and quality of life.
Complex medical dermatology including: epidermolysis bullosa and other genetic skin conditions, autoimmune blistering diseases (such as pemphigus, pemphigoid), hidradenitis suppurativa. I see patients at both Children's Hospital of Colorado and UCHealth, and focus on the transition of care from pediatric to adult practice, particularly for patients with complex or rare skin conditions. As the Associate Director of Clinical Research, I also spend time on clinical research projects including clinical trials.
Care Philosophy
I specialize in complex medical dermatology, including transition of care from pediatric to adult care. I strive to provide compassionate, personalized treatment for the whole patient, recognizing that skin diseases can impact a patient's emotional well-bring and quality of life.
Volunteer Activities
I volunteer at Camp Spirit (a winter camp for children with recessive dystrophic epidermolysis bullosa) and Camp Wonder (a summer camp for children with skin diseases).
Public Speaking
Yes
I volunteer at Camp Spirit (a winter camp for children with recessive dystrophic epidermolysis bullosa) and Camp Wonder (a summer camp for children with skin diseases).
Public Speaking
Yes